Barclays Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective raised by equities research analysts at Barclays from $5.00 to $10.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 106.19% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the stock. Robert W. Baird dropped their price target on shares of Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright lifted their target price on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.20.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $4.85 on Tuesday. The stock has a 50 day moving average of $5.46 and a 200 day moving average of $8.84. The firm has a market capitalization of $41.56 million, a price-to-earnings ratio of -4.75 and a beta of 0.33. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $17.85.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Monday, May 12th. The company reported ($2.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.21) by $1.44. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $35.12 million. Analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds have recently made changes to their positions in KPTI. Velan Capital Investment Management LP acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $27,000. Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter worth $31,000. TD Waterhouse Canada Inc. acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter worth $32,000. Two Sigma Advisers LP increased its position in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after acquiring an additional 45,400 shares during the period. Finally, Opti Capital Management LP acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).